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Abstract
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Human intestinal infections with the nematode Strongyloides stercoralis remain a significant
problem worldwide and a vaccine would be a useful addition to the tools available to prevent and
control this infection. The goal of this study was to test single antigens for their efficacy in a
vaccine against S. stercoralis larvae in mice. Alum was used as the adjuvant in these studies and
antigens selected for analysis were either recognized by protective human IgG (Ss-TMY-1, SsEAT-6, and Ss-LEC-5) or were known to be highly immunogenic in humans (Ss-NIE-1 and SsIR). Only mice immunized with the Ss-IR antigen demonstrated a significant decrease of
approximately 80% in the survival of larval parasites in the challenge infection. Antibodies,
recovered from mice with protective immunity to S. stercoralis after immunization with Ss-IR,
were used to locate the antigen in the larvae. Confocal microscopy revealed that IgG from mice
immunized with Ss-IR bound to the surface of the parasites and observations by electron
microscopy indicated that IgG bound to granules in the glandular esophagus. Serum collected
from mice immunized with Ss-IR passively transferred immunity to naïve mice. These studies
demonstrate that Ss-IR, in combination with alum, induces high levels of protective immunity
through an antibody dependent mechanism and may therefore be suitable for further development
as a vaccine against human strongyloidiasis.

Keywords
Strongyloides stercoralis; Ss-IR; recombinant vaccine

© 2011 Elsevier Ltd. All rights reserved.
*
Corresponding author: David Abraham, Ph.D., Department of Microbiology and Immunology, Thomas Jefferson University, 233
South 10th Street, Philadelphia, PA 19107, Telephone: 215-503-8917, Fax: 215-923-9248, David.Abraham@Jefferson.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Abraham et al.

Page 2

1. Introduction
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Human infection with Strongyloides stercoralis remains a significant health problem in both
resource-rich and resource-poor nations [1] and is estimated to infect 30–100 million people.
It is a nematode infecting humans, primates and dogs that causes a range of relatively benign
symptoms during acute infection. Chronic infections may persist for the lifetime of the host
and are commonly subclinical. However, chronically infected individuals who become
immunosuppressed often because of corticosteroid treatment or infection with HTLV-1 can
develop hyperinfection syndrome, a condition that can be life threatening [2–4]. Although
chemotherapy (albendazole or ivermectin) is available for S. stercoralis infections, efficacy
is rarely 100% [5–6] and the potential for drug resistance is real [7]. Recent findings in
humans infected with Onchocerca volvulus confirm the potential for worms to develop
resistance to ivermectin [8]. Moreover, treatment of the potentially lethal hyperinfection
syndrome remains problematic. Thus, given the potential for fatal disease associated with S.
stercoralis infection, the difficulty in treatment of hyperinfection, and the potential for
resistance to the drugs used to treat S. stercoralis, there remains a need for prophylactic
vaccines against this infection.
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Many approaches have been tested in attempts to produce experimental vaccines against
nematode infections using a plethora of antigen sources, formulations and immunization
protocols, with levels of reduction in worm burden induced by these vaccines ranging from
30–90% [9–10]. Among the intestinal helminths, experimental vaccines against hookworm
infections have been developed using single antigens derived from larvae [11–15] or adult
worms [16] and administered with various adjuvants including alum [12–13, 16]. There was
a reduction of approximately 30% in challenge hookworm survival in animals immunized
with these vaccines [11, 14–16]. This relatively low level of protection, however, was
sufficient to move one of these vaccines toward clinical development and human testing
[12].
The immune response to S. stercoralis, though poorly characterized is required for the
control of infection and the prevention of hyperinfection [17]. Immunization of mice with S.
stercoralis live larvae resulted in high levels of protective immunity that was shown to be
antibody dependent [18–21]. In addition, immunization of mice with alum-adjuvanted
soluble proteins derived from S. stercoralis larvae also generated antibody-dependent
protective immunity. Antibodies from these protected mice were used to affinity purify and
isolate protective S. stercoralis antigens; these antigens, when pooled, induced a significant
protective immunity, with 83% of the challenge larvae killed [22].
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Antibodies from humans chronically-infected with S. stercoralis were also effective at
killing S. stercoralis larvae. Immunization of mice with antigens recognized by “protective”
human IgG with alum induced a 76% reduction in larval survival [20]. This same human
IgG pool was used to identify specific vaccine candidates, three of which (SsTMY-1, SsEAT-6, and Ss-LEC-5) could be characterized at a molecular level. When used in DNAbased immunization protocols, only Ss-eat-6 induced a 35% reduction in larval survival.
Serum from mice immunized with the DNA encoding Ss-eat-6 was also capable of
transferring this partial immunity [23].
The goal of this study was to test single protein antigens for their efficacy in a vaccine
against S. stercoralis larvae in mice. Alum was selected as the adjuvant to be used in these
studies based on past performance in vaccines against S. stercoralis [20, 22] and because it
preferentially induces Th2 responses [24–25], which are critical in the protective immune
response induced by live S. stercoralis larvae [26]. Antigens selected for this study were
either recognized by protective human IgG (Ss-TMY-1 Ss-EAT-6, and Ss-LEC-5 [23]) or
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were known to be highly immunogenic in humans and Strongyloides-specific (Ss-NIE-1 and
Ss-IR [27]). Of the five antigens tested, only Ss-IR was able to consistently induce a high
level of antibody dependent protection.

2. Materials and Methods
2.1 Production of the antigens
The DNA of each of the potential antigens - Ss-tmy-1(BE579623), Ss-eat-6 (BE581796),
Ss-lec-5 (BG227948), Ss-nie-1 (AF136445.1), and Ss-ir (EU285565.1) - was subcloned by
PCR from plasmids containing the entire coding sequence (synthesized by Genscript
[Piscataway, NJ] with codon usage optimized for expression in baculovirus) into Gateway
Entry™ plasmids using sequence specific oligonucleotides. Each of these 5 separate
Gateway Entry plasmids were used to make three Gateway Destination™ vectors for
expression in Escherichia coli, baculovirus, and Kluyveromyces lactis respectively. For any
given antigen, only a single expression system was used for antigen production based on the
system that gave the highest expression level and ease of purification in preliminary testing.
The expression of the purified proteins can be viewed in Figure 1.
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Each protein was cloned by PCR from plasmid DNA [28] using primers corresponding to
the 5′ and 3′ ends of the mature Ss-IR, Ss-EAT-6, Ss-LEC-5, Ss-NIE, Ss-TMY-1 gene and
an adapter-overlap to introduce Gateway recombination sites and an insect cell GP67 signal
peptide leader sequence into the gene. PCR was carried out using Phusion™ polymerase
(New England Biolabs) under standard conditions using a 20 second extension time. The
final PCR product contained the mature gene with a GP67 leader sequence at the 5′ end
preceded by a Gateway attB1 site, and a His6 tag at the carboxyterminal end followed by a
Gateway attB2 site. The PCR products were cleaned using the QiaQuick™ PCR purification
kit (Qiagen), and recombined into pDonr253 using the Gateway BP recombination reaction
(Invitrogen) with the manufacturer’s protocols.
2.1.1 Subcloning of Ss-IR-His6—The sequence-verified Entry clone was subcloned by
Gateway LR recombination (Invitrogen) expression vectors. The expression clones were
then transformed into E. coli DH10Bac (Invitrogen), and plated on selective media
containing gentamicin, kanamycin, tetracycline, IPTG, and X-gal as per the manufacturer’s
protocols. White colonies were selected from these plates, and DNA was generated by
alkaline lysis plasmid preparation, and verified by PCR amplification.
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2.1.2 Expression of GP67 -His6 constructs in High Five (H5) insect cells—The
bacmid DNA was transfected into Sf-9 cells to create a recombinant baculovirus stock. The
bacmid DNA was combined with Insect Gene Juice (Novagen) transfection reagent and then
mixed with 100ml of Sf-9 cells at 1.5×106/ml in HyClone Insect-SFX medium (HyClon,
Logan, UT). Large-scale expression was performed in Corning three liter Erlenmeyer flasks
(Corning, NY). The cell density at infection was 1.53×106/ml and the culture was infected at
a multiplicity of infection (MOI) of 3. Following incubation on a shaker at 100 rpms at 21°
C for 72 hours the supernatant was collected.
2.1.3 Purification of His6 containing proteins—Culture supernatant (200 ml) from
the insect/baculovirus or yeast expression was dialyzed twice (4 hr each) against 4 liters of
20 mM HEPES, pH 7.3, 300 mM NaCl. Sample was adjusted to 45 mM imidazole and
applied to a 1 ml Histrap column (GE Healthcare, pre-equilibrated to the sample buffer
conditions) using an AKTA Purifier FPLC (GE Healthcare). Sample was applied at 0.2 ml/
min, washed to baseline absorbance (A280) and proteins eluted with a linear gradient of
imidazole from 45 mM to 400 mM over 20 ml. Elution was collected in 40 × 0.5 ml
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fractions and these were analyzed by SDS-PAGE with Coomassie staining. Positive
fractions were pooled and the sample dialyzed (as above) to 1xPBS, pH 7.2. Sample (8 ml)
was concentrated to 0.7 ml using an Amicon Ultra (Millipore) 5K MWCO concentrator unit.
2.2 Animals
Male BALB/cByJ mice, six to eight weeks old, were obtained from Jackson Laboratory (Bar
Harbor, ME). Animals were housed in filter-top microisolator boxes (Lab Products Inc.,
Maywood, NJ) in pathogen-free conditions, under light- and temperature-controlled
conditions in the Thomas Jefferson University animal facility. All protocols utilizing
animals were reviewed and approved by the Institutional Animal Care and Use Committee
(IACUC) of Thomas Jefferson University.
2.3 Challenge infections in diffusion chambers
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Strongyloides stercoralis larvae were cultured from the fresh stools of infected laboratory
dogs. Larvae were harvested from charcoal cultures and washed via centrifugation and
resuspension in sterile 1:1 NCTC-135 and IMDM medium supplemented with 100 U/ml
penicillin, 0.1 mg/ml streptomycin (Cellgro, Manassas, VA), 0.1 mg/ml gentamicin
(Invitrogen, Carlsbad, CA) and 0.25 mg/ml levaquin (Ortho-McNeil, Raritan, NJ). Diffusion
chambers were constructed from 14 mm Lucite rings covered with 2.0 μm pore-size
polycarbonate membranes (Millipore, Bedford, MA) using cyanoacrylate adhesive
(Superglue Corp., Hollis, NY) and fused together with an adhesive consisting of 1:1 1,2dichloroethane (Fisher Scientific, Pittsburgh, PA) and acryloid resin (Rohm and Haas,
Philadelphia, PA) and then sterilized via 100% ethylene oxide followed by 12 hours of
aeration.
2.4 Immunization and challenge protocol
Mice were immunized with 25 μg of each recombinant antigen in 0.1 ml of PBS with 0.1 ml
of 1:10 Rehydragel LV (alum) in PBS (General Chemical, Parsippany, NJ) for a 0.2 ml
injection. Mice were immunized with the solution subcutaneously in the nape of the neck on
day 0 followed by a booster immunization 14 days later with the same quantity of antigen
with alum. On day 28 mice were challenged with a diffusion chamber containing 50 larvae
implanted in a subcutaneous pocket on the rear flank of the mouse. Four days after
implantation, the diffusion chambers were recovered and larval survival was determined
based on morphology and mobility of the worms. Serum was collected for subsequent
antibody analysis. Host cells within the diffusion chamber were analyzed by centrifugation
onto slides using a Cytospin 3 (Shandon Inc., Pittsburgh, PA) and then stained for
differential counts with DiffQuik (Baxter Healthcare Corp., Miami, Florida.
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2.5 ELISA
Serum levels of antigen-specific IgG antibodies were measured by ELISA. Maxisorp 96
well plates (Nunc Nalgene International, Rochester, NY) were coated with a 2 μg/ml
solution of recombinant antigen in 50 mM Tris-Cl pH 8.8 overnight at 4° C. Plates were
blocked with borate buffer solution (0.17 M Boric Acid, 0.12 M NaCl, 1 mM EDTA, 0.25%
BSA, 0.05% Tween 20, pH 8.5) (BBS) for 1 hour room temperature. Individual sera were
diluted in BBS and incubated at 4° C overnight. Biotinylated anti-mouse IgG (Vector
Laboratories Inc., Burlingame, CA) were diluted 1:250 for 1 hour room temp, followed by
Extravidin peroxidase diluted 1:1000 (Sigma, St. Louis, MO) for 30 minutes. The
peroxidase substrate ABTS (one component, KPL, Gaithersburg, MD) was added and
optical densities were read at 410 nm in a Bio-Rad iMark Microplate reader (Bio-Rad,
Hercules, CA).
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2.6 Electron microscopy
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Larvae were fixed for 30 min in 0.25% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4,
containing 1% sucrose, and were then processed for immuno-electron microscopy. Thin
sections of embedded larvae were incubated with purified IgG from naïve and immunized
mice, followed by incubation with a suspension of 15 nm gold particles coated with protein
A, as previously described [28].
2.7 Confocal microscopy
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Larvae of S. stercoralis were fixed overnight in 4% paraformaldehyde at 4°C and then
prepared for immunofluorescence confocal microscopy. Whole larvae were washed three
times with PBS and incubated in goat serum blocking buffer (10% goat serum, 0.5% Triton
X-100, 0.1% sodium azide, PBS) (GSBB) overnight at 4°C. GSBB was removed, and mouse
sera (from immune or non-immune animals), at 1:25 dilution in GSBB, was added and
incubated overnight at 4°C with gentle agitation (500 RPM) (Eppendorf, Thermomixer®).
The samples were then washed three times for 30 minutes each with bovine blocking buffer
(1% bovine serum albumin, 0.5% Triton X-100, 0.1% sodium azide, PBS) (BBB). Alexa
Fluor 488-labelled goat anti-mouse IgG (Invitrogen) antibody was then added (1:1000
diluted in BBB) and incubated overnight at 4°C with gentle agitation (500 RPM). The
following day 0.05 mg/ml of 4′,6-diamidino-2-phenylindole (DAPI)(Pierce) was added to
visualize the larvae nuclei and incubation continued for one hour. The larvae were then
washed three times for 30 minutes each with PBS at 4°C with gentle agitation (500 RPM).
After washing, the samples were mounted using Vectashield hard set mounting medium
(Vector Laboratories Inc., Burlingame, CA) and examined using a LEICA SP5 X-WLL and
analyzed using IMARIS™ software (v7.2, Bitplane Inc, St. Paul, MN). Additional controls
were performed that included larvae with neither primary or secondary antibody and larvae
with only labeled secondary antibody.
2.8 Serum transfer
Serum from naïve and immunized mice collected at the conclusion of the above experiments
were pooled and filter sterilized with a 0.2 μm pore size syringe filter and stored at −80° C.
Passive transfer of the whole serum was done by mixing 100 μl of serum with 100 μl PBS
and injecting it into the subcutaneous pocket surrounding the implanted diffusion chamber at
the time of challenge. Recovery of diffusion chambers was at 24 hours post challenge for
evaluation of larval survival and infiltrating cells.
2.9 Statistical analyses
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The number of animals utilized for each of the test conditions is provided in the Figure
legends. Data were analyzed by multifactorial analysis of variance ANOVA in Systat v.11
(Systat, Inc., Evanston, Illinois). Probability values less than 0.05 were considered
significant.

3. Results
3.1 Characteristics of the antigens
Recombinant antigens Ss-IR, Ss-LEC-5, Ss-Eat-6, and Ss-NIE were prepared for the
vaccination studies using a baculovirus expression system and Ss-TMY-1 was expressed in
K. lactis. On SDS-PAGE Ss-IR had a MW of ~31 kDa, Ss-LEC-5. had MW of ~15, 18 23
and 25 kDa, Ss-EAT-6 had a MW of ~26 kDa, Ss-TMY-1 had MW of ~8,11, 35 and 37 kDa
and Ss-NIE-1 had a MW of ~30–34 kDa.
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3.2 Immunization and challenge
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Mice were immunized with recombinant antigens in alum: (1) Ss-EAT-6, (2) SS-TMY-1,
(3) Ss-LEC-5 (4) Ss-NIE and (5) Ss-IR. After two immunizations the mice received a
challenge infection consisting of 50 larvae contained within a diffusion chamber. Only mice
immunized with the Ss-IR antigen demonstrated a significant decrease, of approximately
80%, in the survival of the parasites in the challenge infection (Figure 2A). The total number
of cells and the differential analysis of the cells that migrated into the parasite
microenvironment indicated that there were no differences in the number or types of cells
based on immunization or exposure to alum for each of the antigens tested. Representative
data are presented for the cells recruited into the diffusion chambers implanted in mice
immunized with Ss-IR antigen (Figure 2B). IgG antibody responses were measured and all
immunized mice developed IgG antibody response to the antigen with which they were
immunized (Figure 2C). Based on these initial findings, two additional sets of vaccination/
challenge studies were performed. Vaccination with the same lot of Ss-IR used in the initial
study and with a second lot of SsIR prepared ~ 12 months after the initial preparation gave
the same degree of protection as seen initially (Figure 3).
3.3 Location of Ss-IR in larvae
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Antibodies, recovered from mice with protective immunity to S. stercoralis after
immunization with Ss-IR, were used to locate the antigen in the larvae. Confocal
microscopy on intact worms revealed that IgG from mice immunized with Ss-IR bound to
the surface of the parasites (Figure 4). By immuno-electron microscopy on fixed sectioned
parasites, Ss-IR was localized to granules in the glandular esophagus (Figure 5). Taken
together, these data suggest that the location of the Ss-IR protein makes it an attractive target
for immune-mediated clearance and/or killing.
3.4 Passive transfer of immunity
Serum collected from the mice immunized with Ss-IR was subcutaneously transferred into
naïve mice. The mice then received challenge infections in diffusion chambers implanted for
24 hours. Parasites were killed in mice that had passive transfer of serum from immunized
mice (Figure 6A). Furthermore, cells found in the diffusion chambers did not differ between
mice that received serum from immunized mice and serum derived from naïve mice.
Neutrophils were the predominant cell type migrating into the parasite microenvironment
(Figure 6B).

4. Discussion
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The objective of this study was to evaluate recombinant antigens for their efficacy in a
vaccine against S. stercoralis larvae. Three antigens, Ss-TMY-1, Ss-EAT-6, Ss-LEC-5 were
selected because of their recognition by IgG from humans which was effective at killing the
worms in collaboration with cells. In addition, Ss-eat-6 induced a significant reduction in
larval survival after DNA immunization [23]. Two antigens, Ss-NIE-1 and Ss-IR, were
selected based on their high degree of immunogenicity in humans infected with S.
stercoralis [27, 29–31]. Results from the current study demonstrate that immunization with
the single antigen Ss-IR induced high and consistent levels of protective immunity.
It was surprising that the antigen Ss-IR was protective whereas other immunogenic antigens
or those identified by protective antibodies from humans were not protective. After
immunization all of the antigens induced significant IgG responses, and even though SsTMY-1 induced the greatest levels of antigen specific IgG it was not protective. It is
possible that antigens failed to induce protective immunity either because the target in the
worm was inaccessible to the immune system or because these antigens required a different
Vaccine. Author manuscript; available in PMC 2012 October 19.
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adjuvant to be effective, as has been seen in vaccine studies with the related parasite
Strongyloides venezuelensis [32].
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Based on analyses using confocal microscopy, it was determined that IgG from mice
immunized with Ss-IR bound to the surface of the parasites. Proteomic analysis of S.
stercoralis larvae identified the Ss-IR antigen after a short incubation in trypsin, suggesting
that the antigen was on the larval surface [33]. However, using electron microscopy it was
determined that IgG from mice immunized with Ss-IR bound to granules in the glandular
esophagus. The reason why the two methods used to localize the antigens identified
different locations may be due to the differences in fixation processes that cause changes in
the retention of antigenicity or it may be that antibody could not penetrate into worms
prepared for confocal microscopy. Protective IgM from mice immunized with live larvae
bound to the surface of the cuticle, basal cuticle-hypodermis, coelomic cavity and glandular
esophagus whereas protective IgG bound only to the basal cuticle-hypodermis and the
coelomic cavity [21]. Antigens recognized by IgG from mice immunized with deoxycholate
soluble proteins were found on the muscles and nerve cords [22]. Finally, antigens
recognized by the protective human IgG were found predominantly on the surface and
internal components of the cuticle and on the glands surrounding the esophagus [20]. The
location of Ss-IR is therefore most similar to the site of the antigens recognized by the
protective human IgG.
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Although it appears that protective immunity induced by immunization of mice with Ss-IR
in alum is antibody dependent, the exact mechanism has not been defined. Antibodies from
mice and humans require neutrophils [20–21, 34] and complement [19–20, 35] to kill the
worms. Furthermore, IgG from mice immunized with live larvae killed the challenge
infection through a antibody dependent cellular cytotoxicity (ADCC) dependent mechanism,
whereas IgM from mice immunized with live larvae, IgG from mice immunized with
soluble antigens and human IgG all killed the worms through ADCC independent
mechanisms [20–21]. The localization of Ss-IR on the surface of the worm would be
conducive for an ADCC based mechanism whereas the internal location of the antigen
would be supportive of an ADCC independent mechanism. It is indeed possible that both
mechanisms may be functioning and this might explain the potency of the antigen in a
vaccine.
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In conclusion, Ss-IR has been identified as a highly effective antigen for use in a vaccine
against S. stercoralis. The mechanism of action appears to be antibody dependent and the
observation that it functions so successfully with alum as its adjuvant suggests that a Th2
response may be required. In addition, the fact that alum is widely used as an adjuvant in
humans adds to the potential for this vaccine to be used as a prophylactic vaccine in humans
protecting them from infection with S. stercoralis.
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•

Mice immunized with Ss-IR antigen develop resistance to Strongyloides
stercoralis

•

Ss-IR antibodies were localized to the parasite surface and glandular esophagus

•

Serum collected from immunized mice passively transferred immunity

•

Ss-IR may be suitable as a vaccine against human strongyloidiasis
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Figure 1.

Coomassie-stained SDS-PAGE of purified Ss-IR from two different runs as well as purified
Ss-LEC-5, Ss-Eat-6, Ss-TMY-1 and Ss-NIE prepared for the vaccination studies. Molecular
weight markers (MW) are recorded for individual analyses.
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Figure 2.

Successful immunization of mice with Ss-IR in alum. Mice (n=6) were immunized with
recombinant antigens Ss-EAT-6, Ss-TMY-1, Ss-LEC-5, Ss-NIE-1 or Ss-IR in alum, with
alum alone or left unvaccinated (No treatment). (A) Mean percent larval survival ± standard
deviations of the challenge larvae is presented. (*) = statistically significant difference
between larval recoveries from Ss-IR immunized mice and all other groups. (B) Means ±
standard deviations of the total cells, neutrophils (PMN), macrophages (Mφ) and eosinophils
(EOS) infiltrating into the diffusion chamber. (C) IgG antibody titers against homologous
antigens in mice immunized with the 5 recombinant antigens.
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Figure 3.

Induction of protective immunity by different batches of baculovirus produced Ss-IR. Mice
(n=6) were immunized with 2 independent productions of recombinant antigens Ss-IR in
alum or with alum alone. Mean percent larval survival ± standard deviations of the challenge
larvae is presented. (*) = statistically significant difference between larval recoveries from
Ss-IR immunized mice and mice vaccinated with alum alone.
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Figure 4.

Confocal microscopic localization of Ss-IR on S. stercoralis larvae using control mouse sera
(alum only immunized; bottom panels) or immune mouse sera (Ss-IR immunized; Top
panels). Ss-IR staining is shown in green; DAPI staining is shown in blue.
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Immunoelectron microscopic localization of Ss-IR using control mouse sera (alum only;
Panel A) or immune mouse sera (Ss-IR immunized; Panel B). Arrows point to the specific
areas of staining. Magnification 11000x.
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Figure 6.

Serum from Ss-IR immunized mice passively transfers immunity to challenge infection.
Mice (n=10) received passive transfer of serum derived from mice injected with alum (alum
serum) or injected with alum and Ss-IR (Ss-IR serum). (A) Mean percent larval survival ±
standard deviations of the challenge larvae is presented. (*) = statistically significant
difference between larval recoveries from mice injected with serum from Ss-IR immunized
mice as compared to mice injected with serum from mice injected with alum alone. (B)
Means ± standard deviations of the total cells, neutrophils (PMN), macrophages (Mφ) and
eosinophils (EOS) infiltrating into the diffusion chamber.
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